Global Transthyretin Market Size By Type (AG-10, ALN-TTRsc02), By Application (Familial Amyloid Neuropathies, Alzheimer's Disease), By Region, And Segment Forecasts, 2023 to 2032

lobal Transthyretin Market Report Description

The Global Transthyretin Market was valued at USD 1.2 billion in 2023 and is projected to reach USD 3.4 billion by 2031, growing at a CAGR of 14.2% during the forecast period from 2023 to 2031. The market growth is primarily driven by the increasing prevalence of transthyretin amyloidosis (ATTR), advancements in diagnostic technologies, and the growing approval of novel therapies. Transthyretin (TTR) is a protein implicated in rare but life-threatening amyloid diseases, leading to a surge in research activities and therapeutic developments across the globe.

Drivers:

Rising Prevalence of Transthyretin Amyloidosis:

The increasing incidence of hereditary and wild-type ATTR, particularly among the aging population, is a significant driver of the market. Improved awareness and diagnostics are enabling early detection, driving demand for transthyretin-targeting therapies.

Advancements in Therapeutics:

The approval of innovative drugs such as tafamidis, patisiran, and inotersen has revolutionized treatment paradigms for ATTR. The ongoing development of gene-silencing and stabilizing therapies is expected to further boost market growth.

Increasing Investments in Rare Disease Research:

Biopharmaceutical companies and research institutions are investing heavily in rare disease therapeutics, including transthyretin amyloidosis, fostering new product development and pipeline expansion.

Restraints:

High Treatment Costs:

Despite advancements, the high cost of transthyretin-targeting therapies remains a barrier to widespread adoption, particularly in low- and middle-income countries.

Limited Awareness in Emerging Regions:

Lack of disease awareness and limited access to diagnostic facilities in developing regions restrict market penetration.

Opportunity:

Expansion in Emerging Markets:

Untapped potential in emerging economies, supported by improving healthcare infrastructure and rising awareness, presents lucrative growth opportunities for market players.

Technological Advancements in Diagnostics:

Next-generation sequencing, advanced imaging, and biomarker development are enabling early and accurate diagnosis, creating favorable conditions for market expansion.

Market by System Type Insights:

Based on system type, the Transthyretin Stabilizers segment accounted for the largest market share in 2023. These include drugs that prevent transthyretin from misfolding, thus slowing disease progression. However, the Gene Silencing Therapies segment is expected to witness the fastest growth due to their potential in halting disease at the molecular level.

Market by End-use Insights:

Hospitals dominated the market in 2023 due to their critical role in diagnosis, treatment, and patient management of ATTR. Specialty clinics and research centers are anticipated to register substantial growth, driven by the rising participation in clinical trials and specialized treatment offerings.

Market by Regional Insights:

North America held the largest market share in 2023, driven by advanced healthcare infrastructure, high disease awareness, and the presence of leading pharmaceutical companies. Asia-Pacific is expected to register the fastest growth rate during the forecast period, propelled by increasing investments in healthcare infrastructure and rising diagnostic capabilities in countries like China, Japan, and India.

Competitive Scenario:

Key players operating in the Global Transthyretin Market include Pfizer Inc., Ionis Pharmaceuticals, Alnylam Pharmaceuticals, BridgeBio Pharma, Eidos Therapeutics, Akcea Therapeutics, Prothena Corporation, and Novo Nordisk A/S. These companies are focusing on strategic collaborations, new product launches, and pipeline expansion to strengthen their market presence.

Key Market Developments:

In 2023, Pfizer Inc. expanded the commercial availability of Vyndamax (tafamidis) for transthyretin amyloidosis in several emerging markets.

In 2024, Alnylam Pharmaceuticals announced positive Phase 3 trial results for vutrisiran, a gene-silencing therapy for ATTR amyloidosis.

In 2025, BridgeBio Pharma collaborated with a leading Japanese pharmaceutical company to expand the development of transthyretin stabilizers in Asia-Pacific.

Scope of Work – Global Transthyretin Market

Report Metric Details

Market Size (2023) USD 1.2 Billion

Projected Market Size (2031) USD 3.4 Billion

CAGR (2023-2031) 14.2%

Key Segments by System Type Transthyretin Stabilizers, Gene Silencing Therapies, Other Emerging Therapeutics

Key Segments by End-use Hospitals, Specialty Clinics, Research Centers

Leading Region North America

Key Players Pfizer Inc., Alnylam Pharmaceuticals, Ionis Pharmaceuticals, BridgeBio Pharma, Prothena Corporation

FAQs:

1. What is the current market size of the Global Transthyretin Market?

The Global Transthyretin Market was valued at USD 1.2 billion in 2023.

2. What is the major growth driver of the Global Transthyretin Market?

The major growth driver is the increasing prevalence of transthyretin amyloidosis and the approval of innovative therapies.

3. Which is the largest region during the forecast period in the Global Transthyretin Market?

North America is expected to maintain its dominance during the forecast period.

4. Which segment accounted for the largest market share in the Global Transthyretin Market?

The Transthyretin Stabilizers segment accounted for the largest market share in 2023.

5. Who are the key market players in the Global Transthyretin Market?

Key players include Pfizer Inc., Alnylam Pharmaceuticals, Ionis Pharmaceuticals, BridgeBio Pharma, Prothena Corporation, and Novo Nordisk A/S.

Would you like me to prepare this as a Word document or any other specific format?